readthroughSign in
Aug 12, 2026Weekly roundup

Boehringer adds cardiac safety trial for verducatib alongside survodutide diabetes study

Boehringer Ingelheim has a new Phase I cardiac safety trial for verducatib and continues recruiting its Phase III survodutide diabetes study.

Boehringer Ingelheim's registry activity this period includes a newly posted early-phase cardiac safety study and continued progress on its Phase III diabetes trial.

  • Verducatib (BI 1291583), Phase I, healthy participants: Trial NCT07760246 is listed as active, not recruiting, with an actual start date of August 20, 2026. The trial is designed to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters1, using moxifloxacin as a positive control, and enrolled 56 participants (actual)1, with estimated primary completion on December 30, 2026.
  • Survodutide (BI 456906), Phase III, type 2 diabetes: Trial NCT07754461 remains listed as recruiting, with an actual start date of August 24, 2026. The study continues to test whether survodutide helps people control their blood sugar2 against placebo, with enrollment of 600 participants (estimated)2 and a primary outcome of absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 412.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.